{"id":52138,"date":"2025-12-29T12:32:01","date_gmt":"2025-12-29T04:32:01","guid":{"rendered":"https:\/\/flcube.com\/?p=52138"},"modified":"2025-12-29T12:32:02","modified_gmt":"2025-12-29T04:32:02","slug":"unipath-bronchoscopic-robot-wins-nmpa-approval-expanding-medbots-surgical-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52138","title":{"rendered":"UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot\u2019s Surgical Portfolio"},"content":{"rendered":"\n

Shanghai MicroPort MedBot (Group) Co., Ltd.<\/strong> (HKG: 2252<\/a>) announced that its self\u2011developed UniPath Electronic Bronchoscopic Surgical Robotic System<\/strong> received approval from China\u2019s National Medical Products Administration (NMPA)<\/strong>. The non\u2011invasive natural orifice transluminal robotic platform enables diagnosis and treatment of early\u2011stage pulmonary lesions without external incisions.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>26\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>UniPath Electronic Bronchoscopic Surgical Robotic System<\/td><\/tr>
Innovation<\/strong><\/td>Non\u2011invasive natural orifice transluminal robotic platform<\/td><\/tr>
Indication<\/strong><\/td>Early diagnosis and treatment of pulmonary micronodules<\/td><\/tr>
Technology<\/strong><\/td>Ultra\u2011smooth, ultra\u2011thin snake\u2011shaped robotic catheter for narrow lesion access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Profile<\/h2>\n\n\n\n
Feature<\/th>UniPath System<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Access Method<\/strong><\/td>Natural orifice (no body surface wounds)<\/td>Reduces patient trauma, infection risk, recovery time<\/td><\/tr>
Catheter Design<\/strong><\/td>Ultra\u2011thin, snake\u2011shaped robotic catheter<\/td>Reaches peripheral bronchioles and deep lung segments<\/td><\/tr>
Core Technologies<\/strong><\/td>Robotic precision control, flexible navigation, intelligent path planning, closed\u2011loop control<\/td>Full lung accessibility, full visualization, precise alignment<\/td><\/tr>
Operational Capability<\/strong><\/td>Stable operation under dynamic breathing conditions<\/td>Enables high\u2011certainty access, puncture, and ablation<\/td><\/tr>
Market Positioning<\/strong><\/td>First domestic bronchoscopic surgical robot<\/td>Addresses unmet need in early lung cancer diagnosis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China Lung Cancer Incidence<\/strong><\/td>~800,000 new cases annually (2025)<\/td>Early-stage detection critical for survival<\/td><\/tr>
Pulmonary Micronodules<\/strong><\/td>30\u201140%<\/strong> of CT scans reveal small nodules<\/td>High demand for minimally invasive diagnostic tools<\/td><\/tr>
Surgical Robot Market<\/strong><\/td>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM)<\/td>Growing at 25\u201130% CAGR in China<\/td><\/tr>
UniPath Peak Sales<\/strong><\/td>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (\u2248\u202fUS$112\u2011170\u202fM)** by 2030<\/td>25\u201130% share of bronchoscopic robot segment<\/td><\/tr>
Competitive Advantage<\/strong><\/td>First NMPA\u2011approved<\/strong> domestic system vs. imported Intuitive Ion<\/td>Cost advantage and localization support<\/td><\/tr>
Policy Support<\/strong><\/td>NMPA Innovative Medical Device pathway<\/td>3\u2011year regulatory exclusivity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n